

1
2
3
4
5 **BEFORE THE WASHINGTON STATE**
6 **OFFICE OF THE INSURANCE COMMISSIONER**

7 In the Matter of

No. G02-45

8 THE APPLICATION REGARDING THE
9 CONVERSION AND ACQUISITION OF
10 CONTROL OF PREMIERA BLUE CROSS
11 AND ITS AFFILIATES.

OIC STAFF'S POST-HEARING
BRIEF

12 COMES NOW the Office of the Insurance Commissioner Staff (OIC Staff) by and
13 through their attorneys of record, MELANIE C. deLEON, Assistant Attorney General, and
14 JOHN F. HAMJE, Special Assistant Attorney General, and pursuant to the Twenty-fifth Order
15 Extending Case Schedule, dated January 12, 2004, submits this post-hearing brief.

16 **I. CASE PROCEDURAL HISTORY**

17 In May 2002, Premera Blue Cross (hereafter "Premera") notified the Washington State
18 Insurance Commissioner and the Attorney General of its intention to reorganize its holding
19 company system to convert from a non-profit company to a for-profit company. *See* Exhibit
20 S-71; S-96. On September 17, 2002, Premera filed its Form A Statement ("Form A") seeking
21 approval for its proposed reorganization. *See* Commissioner's 1¹. Thereafter, Premera
22 supplemented its Form A on October 25, 2002 and January 21, 2003. In addition, on October
23 17, 2003, Premera further supplemented the Form A by filing its executive compensation
24

25
26 ¹ All references to the Commissioner's Exhibits will hereafter be referred to as "Exhibit C-#." Citations
to the hearing transcript shall hereafter be referred at "TR".

1 (stock ownership) plan. *See* Exhibit C-2, Exhibit G-10. Finally, after further discussions
2 with the parties, Premera amended the Form A on February 5, 2004. *See* Exhibit C-2.

3 Premera requests approval for changes in control of its domestic health carriers and
4 insurers by dissolving the non-profit corporations within the system and exchanging their
5 assets for stock of a newly-created for-profit company, New Premera, thus resulting in a
6 reorganization of Premera's holding company system. The proposed transaction is illustrated
7 in Exhibit A-3(a) to the amended Form A Statement. *See* Exhibit C-2. The final steps in the
8 proposal consist of New Premera transferring 100% of its initial stock to the Washington and
9 Alaska foundation shareholders. *See* Exhibit C-2, Exhibit A-3(a).

11 Following lengthy discovery and eight public hearings around the state, this matter
12 proceeded to hearing before the Insurance Commissioner from May 3, 2004, through May 18,
13 2004. 41 witnesses presented live testimony; 9 witnesses submitted unsworn testimony, and
14 thousands of pages of documents and prefiled testimony were admitted into the record. The
15 OIC Staff will not reiterate the extensive testimony in this portion of its post-hearing brief but
16 rather will refer to applicable portions in its argument below.

18 II. ISSUES

19 A. Whether Premera's application should be denied because the transaction is not fair and
20 reasonable in that the proposed transaction does not result in the transfer of the fair market
value of Premera's assets to the foundation shareholders.

21 B. Whether Premera's application should be denied because the transaction treats subscribers
22 unfairly and unreasonably, is not in the public interest and is likely to be hazardous to the
insurance-buying public.

23 C. Whether Premera's application should be denied because the transaction will result in the
24 entrenchment of the current board of directors and executive management, and thus is not in
25 the best interests of subscribers, results in a hazard to the insurance buying public and is not in
the public interest.

26 D. What is the proper allocation of assets between the States of Washington and Alaska?

1 E. Whether, if the Commissioner determines to approve the conversion, additional conditions
2 should be placed on the transaction.

3 III. LEGAL ARGUMENT

4 **A. The Commissioner's consideration of Premera's Form A application is subject to**
5 **the Washington Holding Company Acts and the Washington Nonprofit**
6 **Corporation Act.**

7 The Commissioner's consideration of Premera's Form A application is subject to
8 review under chapters 48.31B and 48.31C RCW (the Washington Holding Company Acts) as
9 well as chapter 24.03 RCW (the Washington Nonprofit Corporation Act).

10 **1. RCW 48.31B.015(4)(a) and 48.31C.030(5)(a) provide that the**
11 **Commissioner must affirmatively find that one or more bases for**
12 **disapproval exist or the transaction must be approved.**

13 RCW 48.31B.015 and 48.31C.030 apply to this transaction because the Form A
14 application results in a change in control of several companies within Premera's holding
15 company system including both domestic health carriers and domestic insurers. RCW
16 48.31B.015(1); 48.31C.030(1); 48.31C.160. RCW 48.31B.015 applies to Premera's two
17 domestic insurers involved in the transaction: LifeWise Assurance Company and LifeWise
18 Health Plan of Arizona, Inc. See RCW 48.31C.160. Review under RCW 48.31C.030 is also
19 necessary to determine the factors that apply to the health carriers in the Premera holding
20 company system: Premera Blue Cross and LifeWise Health Plan of Washington. Specifically,
21 the Commissioner shall approve the Form A unless he finds one or more of the following
22 relevant portions of those acts form a basis for disapproval:

23 1. The plans or proposals that the acquiring party has to liquidate the health
24 carrier or insurer, sell its assets, consolidate or merge it with any person, or to
25 make any other material change in its business or corporate structure or
26 management, are unfair and unreasonable to subscribers of the health carrier or
policyholders of the insurer and not in the public interest;²

² RCW 48.31B.015(4)(a)(iv); 48.31C.030(5)(a)(ii)(C)(II).

1 2. The competence, experience, and integrity of those persons who would
2 control the operation of the health carrier or insurer are such that it would not be
3 in the interest of subscribers of the health carrier or policyholders of the insurer
4 and of the public to permit the merger or other acquisition of control;³ or

5 3. The acquisition is likely to be hazardous or prejudicial to the insurance-
6 buying public.⁴

7 In its prehearing brief, Premera argues that the relevant portions of RCW 48.31C.030
8 do not apply to this proceeding unless there is a demonstrated anticompetitive effect. *See*
9 Premera's Hearing Brief, Appendix A. This argument is based upon a statutory interpretation
10 that is flawed.⁵

11 First, Premera asserts that the transaction must be approved unless the Commissioner
12 finds that after the change in control, the domestic health carrier will be unable to satisfy the
13 requirements for registration or that there is substantial evidence that the effect of the change in
14 control may substantially lessen competition or tend to create a monopoly. *Id.* at 32-33.
15 Therefore, Premera's argument continues, that since there is no evidence that either factor is
16 present, the Commissioner must approve the transaction. *Id.* at 35. Finally, Premera argues
17 that because the remaining factors in RCW 48.31C.030 are subsumed under the antitrust
18 inquiry provisions of RCW 48.31C.030(5)(a)(ii)(C), they apply only where the Commissioner
19 has found that a transaction is anticompetitive. *Id.* at Appendix A, 3-4, 8.

20 In reviewing this claim, the Commissioner should turn to the plain language of the
21 statute. To ascertain the legislative intent, it is necessary to examine the language chosen by
22 the legislature.

23
24 ³ RCW 48.31B.015(4)(a)(v); 48.31C.030(5)(a)(ii)(C)(III).

25 ⁴ RCW 48.31B.015(4)(a)(vi); 48.31C.030(5)(a)(ii)(C)(IV).

26 ⁵ There appears to be no dispute that all of the factors contained in RCW 48.31B.015 apply to the two
domestic insurers involved in the transaction: LifeWise Assurance Company and LifeWise Health Plan of

1 *Fraternal Order of Eagles, Tenino Aerie No. 564 v. Grand Aerie of Fraternal Order of Eagles,*
2 148 Wn.2d 224, 239, 59 P.3d 655, *cert. denied* 538 U.S. 1057 (2003). Here, RCW
3 48.31C.030(5)(a) provides, in relevant part, as follows:

4 The commissioner shall approve an acquisition of control ... unless, after a
5 public hearing, he or she finds that:

6 ...

7 (ii) The antitrust section of the office of the attorney general and any federal
8 antitrust enforcement agency has chosen not to undertake a review of the
9 proposed acquisition and the commissioner pursuant to his or her own review
finds that there is substantial evidence that the effect of the acquisition may
substantially lessen competition or tend to create a monopoly in the health
coverage business.

10 If the antitrust section of the office of the attorney general does not undertake
11 a review of the proposed acquisition and the review is being conducted by
the commissioner, then the commissioner shall seek input from the attorney
general throughout the review.

12 If the antitrust section of the office of the attorney general undertakes a
13 review of the proposed transaction then the attorney general shall seek input
14 from the commissioner throughout the review. As to the commissioner, in
making this determination:

15 ...

16 (B) The commissioner may not disapprove the acquisition if the
commissioner finds that:

17 (I) The acquisition will yield substantial economies of scale or
18 economies in resource use that cannot be feasibly achieved in any
19 other way, and the public benefits that would arise from the
economies exceed the public benefits that would arise from more
competition; or

20 (II) The acquisition will substantially increase or will prevent
21 significant deterioration in the availability of health care coverage,
22 and the public benefits of the increase exceed the public benefits that
would arise from more competition;

23 (C) The commissioner may condition the approval of the acquisition on the
24 removal of the basis of disapproval, as follows, within a specified period of
time:

25
26 Arizona, Inc. Premera's Hearing Brief at 30 n. 9; *see* RCW 48.31C.160. The dispute arises only with respect to
the factors that apply to the health carriers: Premera Blue Cross and LifeWise Health Plan of Washington.

1 (I) The financial condition of an acquiring party is such as might
2 jeopardize the financial stability of the health carrier, or prejudice the
interest of its subscribers;

3 (II) The plans or proposals that the acquiring party has to liquidate the
4 health carrier, sell its assets, consolidate or merge it with any person,
or to make any other material change in its business or corporate
5 structure or management, are unfair and unreasonable to subscribers
of the health carrier and not in the public interest;

6 (III) The competence, experience, and integrity of those persons who
7 would control the operation of the health carrier are such that it would
not be in the interest of subscribers of the health carrier and of the
public to permit the merger or other acquisition of control; or

8 (IV) The acquisition is likely to be hazardous or prejudicial to the
9 insurance-buying public.

10 Subsections (B) and (C) above both include language relating to the Commissioner's
11 antitrust inquiry. These provisions are introduced with the language: "As to the commissioner,
12 in making this determination" The words "this determination" relate to the result of the
13 Commissioner's antitrust inquiry. RCW 48.31C.030(5)(a)(ii). Subsection (B) provides that if
14 he finds that the test set forth in either (B)(I) or (B)(II) is met, he may not disapprove the
15 transaction regardless of whether he has finds that "substantial evidence that the effect of the
16 acquisition may substantially lessen competition or tend to create a monopoly in the health
17 coverage business." Both tests contained in subsection (B) substantively relate to the antitrust
18 inquiry and authorize the Commissioner to weigh the public benefits that may be gained from
19 the change in control against the public benefits that would be gained from more competition.
20 The legislature intended that the Commissioner exercise his discretion rather than disapprove a
21 transaction merely because it would result in lessening competition.
22

23 In contrast, subsection (C) presents a different consideration. None of the articulated
24 bases of disapproval set out in (C)(I), (C)(II), (C)(III), or (C)(IV) apply by their terms to an
25 antitrust inquiry. They appear entirely unrelated to the inquiry particularly in light of the use in
26

1 RCW 48.31B.015(4)(a)(iii), (iv), (v), and (vi), of substantially similar language as stand-alone
2 grounds for disapproval. When similar words are used in different parts of a statute, it is
3 presumed that the legislature intended the meaning to be the same throughout. *DeGreif v.*
4 *Seattle*, 50 Wn.2d 1, 20, 297 P.2d 940 (1956). The language used in the former statute, RCW
5 48.31C.015 (4)(a), was not conditioned in any way or even related to the antitrust inquiry. The
6 provisions contained in RCW 48.31C.030(5)(a)(ii)(C) should be given a similar meaning and
7 applied in the same way. Merely subsuming them under the antitrust inquiry provisions does
8 not compel the conclusion that they should be applied any differently than the corresponding
9 provisions in RCW 48.31B.015.
10

11 Further, it makes no sense to condition approval of a transaction that is deficient for
12 anticompetitive reasons upon one of the grounds set forth in RCW 48.31C.030(5)(a)(ii)(C).
13 For instance, what anticompetitive finding may be cured with a conditional approval that
14 speaks to the “competence, experience, and integrity” of those who would control the target
15 health carrier? RCW 48.31C.030(5)(a)(ii)(C)(III). The same may be asked about each of the
16 other bases.⁶ Premera’s interpretation would render these provisions superfluous. In
17 construing a statute, no part should be deemed inoperative or superfluous unless the result of
18 an obvious error. *Cox v. Helenius*, 103 Wn.2d 383, 387-388, 693 P.2d 683 (1985). The OIC
19 Staff’s construction of these provisions supports their robust application in Form A
20 proceedings.
21
22

23 In addition, if Premera’s interpretation is accepted, the Commissioner would be
24 authorized only to review a transaction under RCW 48.31C.030(5)(a)(i) without any
25
26

1 consideration of the bases of disapproval set out in RCW 48.31C.030(5)(a)(ii)(C), if the
2 Attorney General or any federal antitrust enforcement agency undertook a review of the
3 transaction. Taking into consideration the broad scope of these bases, it seems unlikely that
4 the legislature intended to so hamstring the Commissioner.

5
6 Assuming for the purpose of argument only that Premera's proposition that the bases
7 for disapproval set forth in RCW 48.31C.030(5)(a)(ii)(C) are not stand-alone provisions, the
8 language utilized by the legislature does not compel the conclusion that the bases for
9 disapproval are only triggered upon an anticompetitive finding. Premera's Hearing Brief,
10 Appendix A at 4. The introductory language does not condition what follows 4 upon such a
11 finding. "As to the commissioner, in making this determination" requires that the
12 commissioner take into consideration the provisions that follow in formulating his finding
13 regarding the antitrust inquiry. He must determine whether the tests contained in RCW
14 48.31C.030(5)(a)(ii)(B) are satisfied. If they are, he cannot disapprove the transaction on
15 anticompetitive grounds. He must also consider the bases for disapproval set out in RCW
16 48.31C.030(5)(a)(ii)(C). If he finds that one or more are applicable, he may either disapprove
17 the transaction or condition approval if the basis or bases are removed *within the context of his*
18 *antitrust inquiry*. Reliance upon the words "as follows" contained in RCW
19 48.31C.030(5)(a)(ii)(C) to establish that the bases for disapproval are conditioned upon a
20 threshold anticompetitive finding is misplaced. The words merely signal that what follows is a
21 list of the bases for disapproval. Therefore, the Commissioner may rely upon these bases in
22
23
24

25 ⁶ Although it is arguable that the bases for disapproval contained in RCW 48.31C.030(5)(a)(ii)(C)(II) and
26 (IV) encompass anticompetitive findings, that is only possible due to the broad sweep of the language used by the legislature. This is consistent with their use outside of the antitrust context in RCW 48.31B.015(4)(a).

1 connection with making a finding regarding his antitrust inquiry. They are effectively stand-
2 alone bases for disapproval that represent components of the Commissioner's antitrust inquiry.

3 Even if Premera's interpretation concerning RCW 48.31C.030(5)(a)(ii)(C) were
4 correct, it does not take into consideration the authority granted to the Commissioner under
5 RCW 48.31C.030(5)(c) which provides: "The commissioner may condition approval of an
6 acquisition on the removal of the basis of disapproval within a specified period of time." The
7 "basis of disapproval" includes those defined as in RCW 48.31C.030(5)(a)(ii)(C) as well as
8 RCW 48.31C.030(5)(a)(i) and (ii). It is a stand-alone provision that allows the Commissioner
9 to use without limitation any basis of disapproval as a condition of approval. In this way, it
10 differs from similar language used by the legislature in RCW 48.31B.015(4)(a)(ii)(C). Thus,
11 since the Commissioner may use those bases of disapproval listed in RCW
12 48.31C.030(5)(a)(ii)(C) as conditions for approval, he may also disapprove a transaction on
13 one or more of these bases without regard to any anticompetitive finding.
14

15
16 **2. Under RCW 48.31B.030 and 48.31C.050, Premera must demonstrate that**
17 **the terms of the application are fair and reasonable.**

18 RCW 48.31B.030 and 48.31C.050 apply to the application because that the domestic
19 insurers (LifeWise Assurance Company and LifeWise Health Plan of Arizona, Inc.) and
20 domestic health carriers (Premera Blue Cross and LifeWise Health Plan of Washington) are
21 parties to the proposed transaction. RCW 48.31B.030(1)(a); 48.31C.050(1). Thus, the terms
22 of the transaction must be fair and reasonable. RCW 48.31B.030(1)(a)(i); 48.31C.050(1)(a).

23 Premera argues for a narrow construction of the so-called "Form D" provision
24 applicable to domestic health carriers by claiming it only applies to those transactions listed in
25 RCW 48.31C.050(2) where the transaction is not subject to approval elsewhere within
26

1 title 48 RCW.⁷ Premera's Hearing Brief at 57, n. 36. Therefore, the argument is made, none
2 of the standards set out in RCW 48.31C.050(1) apply. This is not a correct interpretation of the
3 applicable provisions.

4 RCW 48.31C.050 provides, in pertinent part, as follows:

5 (1) Transactions within a health carrier holding company system to which a
6 health carrier subject to registration is a party are subject to the following
7 standards:

8 (a) The terms must be fair and reasonable;

9 ...

10 (2) The following transactions, excepting those transactions which are subject to
11 approval by the commissioner elsewhere within this title, involving a domestic
12 health carrier and a person in its health carrier holding company system may not
13 be entered into unless the health carrier has notified the commissioner in writing
14 of its intention to enter into the transaction and the commissioner does not
15 declare the notice to be incomplete at least thirty days before, or such shorter
16 period as the commissioner may permit, and the commissioner has not
17 disapproved it within that period. Unless the commissioner declares the notice
18 to be incomplete and requests additional information, the notice is deemed
19 complete thirty days after receipt of the notice by the commissioner. If the
20 commissioner declares the notice to be incomplete, the thirty-day time period in
21 which the notice is deemed complete shall be tolled until fifteen days after the
22 receipt by the commissioner of the additional information:

23 (a) Sales, purchases, exchanges, loans or extensions of credit,
24 guarantees, or investments if the transactions are equal to or exceed the
25 lesser of (i) two months of the health carrier's annualized claims and
26 administrative costs, (ii) five percent of the health carrier's admitted
assets, or (iii) twenty-five percent of net worth, as of the 31st day of the
previous December;

...

(d) Management agreements, service contracts, and cost-sharing
arrangements;

...

(4) The commissioner, in reviewing transactions under subsection (2) of this
section, shall consider whether the transactions comply with the standards set
forth in subsection (1) of this section.

⁷ Premera implies that the standards enumerated in RCW 48.31B.030(1) are applicable to this transaction since the limitation language relied upon in RCW 48.31C.050(2) is not present. Premera's Response to the OIC Staff's Prehearing Memoranda at 3, n. 2. OIC Staff's position is that RCW 48.31B.030(1) applies to the Form A.

1 Subsection (1) contains the general rule applicable to all transactions within a health
2 carrier holding company system. All regulated companies must adhere to the standards set
3 forth in this subsection. Failure to do so may result in sanctions. *See, e.g.*, RCW 48.31C.080,
4 .090, .120.

5
6 Subsection (2) establishes a procedure for a health carrier to obtain prior approval for
7 certain enumerated transactions. The transactions may not be consummated until the carrier
8 notifies the Commissioner. The transaction is deemed approved if the Commissioner fails to
9 take certain actions within the prescribed periods of time. The subsection excludes from this
10 procedure "those transactions which are subject to approval by the commissioner elsewhere
11 within this title." That means that where a different procedure is required for approval, such as
12 that mandated by RCW 48.31C.030(4), that procedure must be followed rather than the strict
13 deemer provisions contained in subsection (2). This provision is necessary to prevent conflict
14 between dissimilar statutory procedural requirements.

15
16 Subsection (4) provides that when a transaction is submitted and reviewed under
17 subsection (2), the Commissioner is required to consider the standards set out in subsection (1).
18 Subsection (4) does not limit the application of the standards set forth in subsection (1). It
19 merely specifies that those standards be applied under the procedures established by subsection
20 (2).
21

22 If Premera's narrow interpretation of these provisions is accepted, it would mean that
23 the Commissioner could not enforce the standards set out in subsection (1) except where a
24 health carrier submitted the transaction for prior approval under the procedure established in
25 subsection (2). Thus, if the transaction were subject to the approval of the Commissioner
26

1 under RCW 48.31C.030, the standards would not apply. Premera's Hearing Brief at 57, n. 36.
2 This result is inconsistent with the authority granted to the Commissioner in chapter 48.31C
3 RCW. The Commissioner may enforce the standards established in subsection (1) without
4 regard to whether the health carrier obtained approval for the transaction under the procedures
5 set out in subsection (2). RCW 48.31C.090(3) provides that if a health carrier "has engaged in
6 a transaction or entered into a contract that is subject to RCW 48.31C.050 and 48.31C.060 and
7 that would not have been approved had approval been requested," the Commissioner may issue
8 a cease and desist order or void such contract.⁸ This means the Commissioner may apply the
9 standards set forth in RCW 48.31C.050(1) in determining whether the transaction would have
10 been approved. The legislature did not limit the application of this provision to transactions
11 under RCW 48.31C.050(2) but, instead referenced the entire section. Therefore, it did not
12 exclude from the embrace of this statute those transactions which may be applied under RCW
13 48.31C.030. In fact, the legislature prohibited the application of RCW 48.31C.090 to
14 acquisitions under RCW 48.31C.020. RCW 48.31C.090(6). If it had not intended that the
15 standards be enforced in a Form A proceeding, the legislature would also have excluded RCW
16 48.31C.030. *See Bour v. Johnson*, 122 Wn.2d 829, 836, 864 P.2d 380 (1993) ("Legislative
17 inclusion of certain items in a category implies that other items in that category are intended to
18 be excluded.").

19
20
21
22
23
24
25
26

⁸ The Form A is subject to both RCW 48.31C.050 and 48.31C.060.

1 **3. The provisions of RCW 24.06.265 and Premera's Articles of Incorporation**
2 **apply to the Application because they require Premera to distribute its net**
3 **assets as part of any dissolution.**

4 RCW 24.06.265 requires Premera to transfer its assets to another nonprofit
5 organization. In this case, Premera has selected a Washington and Alaska foundation to
6 transfer its assets. See Exhibit C-2. Finally, Premera's own Articles of Incorporation also
7 require such a transfer. See TR 1282-83, 2118-19, 2120-21; Exhibit P-87 at 20-21.

8 **B. Premera's application should be denied because the transaction is not fair and**
9 **reasonable in that the proposed transaction does not result in the transfer of the**
10 **fair market value of Premera's net assets to the foundations shareholders.**

11 A determination of whether Premera's net assets are subject to a charitable trust
12 analysis is irrelevant because Premera has conditioned its application on transfer of fair
13 market value.

14 Premera's application contemplates the creation of two nonprofit foundations that are
15 the intended recipients of Premera's net assets upon its dissolution. As such, the
16 Commissioner must review the transaction to ensure that the value of Premera is preserved for
17 lawful uses under RCW 24.03.225(3). See generally Exhibit I-2. The Attorney General,
18 rather than the Commissioner, is responsible for determining the ultimate use of the
19 distributed assets. RCW 24.03.230. In addition, the Attorney General is exclusively
20 responsible for determining to what extent, if any, Premera's assets are subject to charitable
21 use restrictions whether imposed by statute or by common law. *Id.* Premera's application is
22 structured to avoid the necessity of making this determination since it is intended to transfer
23 the fair market value of Premera's assets to the foundation shareholders upon dissolution.
24 Therefore, the Commissioner's role is to ascertain whether the Form A application will bring
25 about the intended result. See Exhibit I-2 at 3.
26

1 RCW 48.31B.030(1)(a)(i) states, in relevant part, that “transactions within a holding
2 company system to which an insurer subject to registration is a party . . . must be fair and
3 reasonable.” Similarly, RCW 48.31C.050(1)(a) states that “transactions within a health carrier
4 holding company system to which a health carrier subject to registration is a party . . . must be
5 fair and reasonable.” Under Premera’s current plan of conversion, and for the reasons argued
6 at the hearing, the terms of the transaction are not fair and reasonable and should be
7 disapproved by the Commissioner.
8

9 Regardless of whether Premera is willing to concede that it is obligated to transfer its
10 assets to one or more non-profit corporations under RCW 24.03.225(3) or the common law
11 charitable trust or *cy pres* doctrines, it is required to do so under its Articles of Incorporation
12 and RCW 24.03.225(4) and (5). TR 1282-83, 2118-19, 2120-21; Exhibit P-87 at 20-21.
13 Testimony from Patrick Cantilo, the OIC Staff’s legal consultant, as well as Premera’s own
14 legal expert, John Steel, is unanimous that transfer of 100 percent of the stock in New Premera
15 to the Washington and Alaska Foundations is equivalent to transfer of fair market value. TR
16 1287-88, 2045-49, 2093-94.
17

18 Further, Premera’s own documents contradict the position that Premera appears to take
19 throughout the hearing. The initial Form A application stated that
20

21 PREMERA will adopt and its sole member, the Foundation Shareholder, will approve
22 a Plan of Reorganization and Plan of Distribution pursuant to which PREMERA will
23 dissolve and distribute 100% of its assets, including all the stock of New PREMERA
24 to the Foundation Shareholder.”

25 Exhibit C-1 at 15, item 7(c) (emphasis added). Premera’s revised Form A filed on February 5,
26 2004 contained more narrow language:

PREMERA will adopt and its members, the Washington Foundation Shareholder and
Alaska Health Foundation, will approve a Plan of Reorganization and Plan of

1 Distribution pursuant to which PREMERA will dissolve and distribute 100% of its
2 assets, consisting of all the stock of New PREMERA to the Washington Foundation
Shareholder and Alaska Health Foundation.

3 Exhibit C-2 at 17, item 7(c) (emphasis added). Premera's counsel confirmed that a
4 consequence of approval of the Form A would be the transfer of fair market value to the
5 Washington and Alaska Foundations.

6 Premera has agreed only that it will transfer 100% of its stock to the
7 Foundation Shareholders, which represents the fair market value of
8 the company upon consummation of the conversion transaction.

9 Exhibit S-86 at 3 of Exhibit 7 (emphasis added). Since the Form A application contemplates
10 that fair market value will be transferred to the foundation shareholders, any discussion of
11 whether Premera's net assets are subject to charitable trust limitations is irrelevant. TR 206-
12 07, 2084, 2100; Exhibit I-5 at 3.

13 Next, the structure of Premera's proposal serves to reduce the fair market value of the
14 net assets. The Form A application includes a Registration Rights Agreement (Exhibit C-2 at
15 G-5), the Voting Trust and Divestiture Agreement (Exhibit C-2 at G-4), and the Transfer,
16 Grant and Loan Agreement (Exhibit C-2 at G-3). By these documents Premera imposes
17 restrictions upon the stock to be transferred to the foundations' shareholders. These
18 documents restrict when or if the stock can be sold, how to sell the stock, and rights
19 accompanying the stock. These restrictions represent a substantial impediment to the transfer
20 of fair market value of the stock to the foundations. TR 1367, 1382-83, 1480, 2119. *See*
21 *Mailloux v. Commissioner of Internal Revenue*, 320 F.2d 60, 62 (5th Cir. 1963) (restrictions on
22 stocks may adversely impact the fair market value of that stock).
23
24
25
26

1 The following restrictions have a negative impact on the fair market value of the stock
2 to be transferred to the foundations and thus should result in the Commissioner's disapproval
3 of the application.

4 1. The Unallocated Shares Escrow Agreement (USEA) requires the Washington
5 Foundation to sell not less than 10% of its stock in the initial public offering, forcing
6 the foundation to sell at a time when the stock price may be low or unacceptable⁹. TR
7 1475-78, 2051-52.

8 2. The Voting Trust and Divestiture Schedule treats both the Washington and Alaska
9 foundations as one entity. By applying the divestiture requirements to both
10 foundations in the aggregate, the Washington foundation may be forced to sell a
11 portion of its shares at an unfavorable time or at an unfavorable price if, for any
12 reason, the Alaska foundation elects not to sell any or a sufficient amount by the
13 deadlines. TR 1486-69, 2052-55. This results then in an unacceptable risk to the
14 Washington foundation of not achieving full market value.

15 3. In the Voting Trust and Divestiture Schedule, the Washington foundation would be
16 denied a free vote of its shares in transactions involving the acquisition or exchange of
17 substantial equity in New Premera unless the transactions involve more than 50% of
18 New Premera's equity. TR 1465-66.

19 Furthermore, Premera's self-described plan to seek the amount of \$100 to \$150 million in
20 an initial public offering (IPO) will substantially dilute the value of the Washington
21 foundation's stock in New Premera. TR 915-16, 1363-64, 1370-72. Based on these

22
23
24
25
26 ⁹ The price of stock during an IPO may be artificially low to attract buyers. This discount may be as high
as 15%. TR 1371, TR 2052.

1 restrictions, Premera's plans to dissolve and distribute its assets to the foundations are unfair
2 and unreasonable to policyholders and are subject to disapproval on this issue alone.

3 **C. The Commissioner must disapprove the Form A application because the economic**
4 **impact of Premera's plans to convert is unfair and unreasonable to subscribers of**
5 **the health carrier or policyholders of the insurer and because this conversion is**
6 **likely to be hazardous to the insurance-buying public.**

7 The evidence from the hearing demonstrated that in many parts of Eastern
8 Washington, Premera has the market power to raise premiums above competitive levels.
9 Because Premera has not sufficiently addressed this risk to subscribers or the insurance
10 buying public, this application must be denied.

11 Market power is the power to control prices.¹⁰ Ordinarily, market power is proven by
12 circumstantial evidence. *Image Technical Serv. v. Eastman Kodak Co.*, 125 F.3d 1195 (9th
13 Cir. 1997) ("Kodak"); *Rebel Oil Co., Inc. v. Atlantic Richfield Co.*, 51 F.3d 1421, 1434 (9th
14 Cir.1995) ("Rebel Oil"). To demonstrate market power circumstantially, a party must: (1)
15 define the relevant market, (2) show that the defendant owns a dominant share of that market,
16 and (3) show that there are significant barriers to entry and show that existing competitors
17 lack the capacity to increase their output in the short run." *Rebel Oil*, 51 F.3d at 1434. In this
18 proceeding, Dr. Keith Leffler demonstrated, on the basis of the *Rebel Oil* factors, that Premera
19 has market power over premiums in many parts of Eastern Washington.

20 **1. Definition of The Relevant Market.**

21 The definition of the relevant market requires proof of the product or service that is the
22 subject of the market ("product market"), and of the geographic area in which the firm is
23

24
25 ¹⁰ Few Washington state court decisions address issues of market power, but there are many pertinent
26 federal decisions. Resort to federal antitrust law is expressly authorized by the Legislature. The Legislature
intended Washington's antitrust laws to complement the body of federal antitrust law and, in construing the state

1 alleged to have market power ("geographic market"). The relevant product market
2 encompasses "all products that are 'reasonably interchangeable,' and so can be said to compete
3 with each other for the same buyers' dollars" *Murray Publishing v. Malmquist*, 66 Wn.
4 App. 318, 832 P.2d 493 (1992), quoting *General Business Sys. v. North Am. Philips Corp.*,
5 699 F.2d 965, 972 (9th Cir. 1983); see also *U.S. v. E.I. du Pont de Nemours & Co.*, 351 U.S.
6 377, 394-395 (1956). The geographic market is the area of effective competition within which
7 buyers can turn for alternative sources of supply. *Murray Publishing v. Malmquist*, 66 Wn.
8 App. at 326. The geographic market inquiry attempts to define the area in which customers of
9 the subject firm reasonably can find alternative sellers of the product if the subject firm raises its
10 price or restricts its output.
11

12 This state law definition of the relevant market is entirely consistent with the definition
13 used by the primary federal antitrust enforcement agencies, as stated in the *Horizontal Merger*
14 *Guidelines* of the U.S. Department of Justice and the Federal Trade Commission (hereinafter the
15 "*Merger Guidelines*"). The *Merger Guidelines* provide that the relevant market is defined by
16 examining likely consumer responses to an increase in the price of the subject product by a
17 hypothetical firm having a monopoly over the product:
18

19 Absent price discrimination, a relevant market is described by a product or
20 group of products and a geographic area. In determining whether a hypothetical
21 monopolist would be in a position to exercise market power, it is necessary to
22 evaluate the likely demand responses of consumers to a price increase. A price
23 increase could be made unprofitable by consumers either switching to other
24 products or switching to the same product produced by firms at other locations.
25 The nature and magnitude of these two types of demand responses respectively
26 determine the scope of the product market and the geographic market.

24 *Merger Guidelines*, Exhibit P-96 at 6-7.

25
26 laws, state courts are to be guided by federal decisions dealing with the same or similar matters. RCW 19.86.920;
Boeing Co. v. Sierracin Corp., 108 Wn.2d 38, 738 P.2d 665 (1987).

1 In defining the relevant markets, Dr. Leffler applied the definition described in *Murray*
2 *Publishing v. Malmquist* and in the *Merger Guidelines*. He defined the markets to include
3 commercial insurance to individuals, small groups and large groups in regional areas in
4 Washington. TR 1756-57. He separated commercial insurance from governmental insurance
5 like Medicare, Medicaid and the Basic Health Plan, because consumers with commercial
6 plans will not likely be able to switch to governmental coverage in response to a price
7 increase. TR 1758. For the same reason, he treated individual, small group and large group
8 as separate products. TR 1760. Consumers cannot switch between these types of coverage.
9 The regions constituting the geographic market areas are defined by how far consumers would
10 travel to obtain health care. TR.1757-58. Dr. Leffler's definitions of the relevant markets are
11 supported by common sense, as well as by the foregoing legal authorities.¹¹
12
13

14 ¹¹ During cross-examination of Dr. Leffler, Premera suggested incorrectly that the court in *Rebel Oil*
15 ruled that a relevant market should be defined on the basis of supply considerations, as well as on the basis of the
16 demand considerations specified in the *Merger Guidelines*. Although the *Rebel Oil* court did state in dictum that
17 market definition should include supply considerations, that is not what the court did. The issue was whether the
18 product market should include both self-service gasoline sales and full-service sales. The court did not rule that
19 consumers would switch from self serve to full serve, so that full-service should be included in the product
20 market. It ruled that full-service pumps could easily at virtually no cost be converted to self serve. Therefore it
21 included the market share of full serve pumps in computing shares of the market. The court's dictum overlooks
22 the subtle distinction between defining the market and identifying participants in the market. The court did not
23 expand the product market to include full serve – it determined that full-service pumps could be easily be
24 brought into the self serve product market. The distinction overlooked by the court is expressly addressed in the
25 *Merger Guidelines*:
26

“Once defined, a relevant market must be measured in terms of its participants and
concentration. Participants include firms currently producing or selling the market's products in
the market's geographic area. In addition, participants may include other firms depending on
their likely supply responses to a 'small but significant and nontransitory' price increase. A
firm is viewed as a participant if, in response to a 'small but significant and nontransitory' price
increase, it would likely enter rapidly into production or sale of a market product in the market's
area, without incurring significant sunk costs of entry and exit. Firms likely to make any of
these supply responses are considered to be 'uncommitted entrants' because their supply
response would create new production or sale in the relevant market and because that
production or sale could be quickly terminated without significant loss.”

Exhibit P-96 at 8-9. Thus, notwithstanding the *Rebel Oil* court's dicta, its holding on market measurement is
consistent with the *Merger Guidelines*. Given the court's conclusions about the ease of converting full-serve

1 **2. Market Dominance in Areas of Eastern Washington.**

2 Dr. Leffler properly concluded that Premera has market dominance in selling individual
3 and small group plans in the fourteen counties in Eastern Washington in which it has both the
4 BCBSA trade marks. TR 1764.¹² Premera's market share in these markets exceeds 80 percent in
5 every case and 90 percent in most cases. Exhibit S-112. Given that a market share of 65 percent
6 generally creates a *prima facie* case of market dominance, Dr. Leffler's conclusions about
7 Premera's market dominance in these counties in Eastern Washington is clearly well-founded.
8

9 **3. Barriers To Entry And Expansion In Eastern Washington Are Supported**
10 **By Extensive Evidence.**

11 Proving market power on the basis of dominant market share involves showing that new
12 competitors face barriers to entry and that current competitors lack the ability to expand their
13 output to challenge a dominant firm's increased prices. *Kodak*, 125 F.3d at 1208. The purpose is
14 to show that the monopoly power will not likely be self-corrected by the market. *Id.*

15 Dr. Leffler determined that there are several barriers to entry and expansion in Eastern
16 Washington. First, he pointed to switching costs. Consumers do not want to have to change
17 doctors in response to a small premium increase, so competing plans would have to offer a
18 provider network as large as Premera's extensive network. TR 1765. Also, employers
19 providing coverage face administrative costs of switching carriers. TR 1765. In addition, the
20 small size of the markets in many areas of Eastern Washington make it unlikely that Premera
21 would face new competition in response to a five to ten percent price increase. TR 1765.
22

23
24 pumps to self serve, the full serve sellers were "uncommitted entrants" whose market shares were properly
included in the measurement of market shares and concentration under the Guidelines.

25 ¹² It should be noted that Dr. Leffler did not consider counties to necessarily constitute the relevant
26 geographic markets. The OIC data used to calculate market shares is reported by county. TR 1759. Dr. Leffler
testified that in some instances like Spokane, metropolitan areas would be the appropriate markets. In others it

1 Finally, Dr. Leffler demonstrated that Premera's control of the Blue Cross and Blue Shield
2 brands gave it a significant advantage in the fourteen-county area. Premera's own market shares
3 in the fourteen counties are much higher than its shares in other Eastern Washington counties,
4 where it faces competition from other "Blue plans." Exhibit S-112. Dr. Leffler also observed
5 that Regence's market shares in Eastern Washington were greatly affected by whether it has the
6 Blue brand. In those counties in which it can use the Blue Shield trade mark, its market share
7 averaged 30 percent, but in the other counties its share averaged only six percent. TR 1766.

9 The United States Supreme Court has recognized the practical reality that switching costs
10 can force customers of a dominant seller to tolerate price increases. *Eastman Kodak Co. v.*
11 *Image Technical Services*, 504 U.S. 451, 112 S.Ct. 2072, 119 L.Ed.2d 265 (1992). Also, it is
12 well established that entry barriers include entrenched buyer preferences. *Kodak*, 125 F.3d at
13 1208; *Rebel Oil*, 51 F.3d at 1439; *see also U.S. Philips Corp. v. Windmere Corp.*, 861 F.2d 695
14 (D.C.Cir. 1988); *Avery Dennison Corp. v. Acco Brands Inc.*, 2000 WL 986995 (C.D.Cal.
15 2000).

17 **4. The market share analysis of Premera's economist is simply not credible.**

18 In striking contrast to Dr. Leffler's careful analysis, Dr. McCarthy offered a market-
19 share theory that ignores basic economic and legal principles and the realities of the market in
20 Eastern Washington. In order to justify a market share under 28 percent for Premera as a
21 seller of health plans, Dr. McCarthy grouped together commercial and governmental
22 coverage, and individual and small and large group plans. TR 527. Dr. McCarthy admitted
23 that buyers of commercial plans could not likely switch to governmental coverage, and, for
24

25
26 would be counties. But his market share calculations for Eastern Washington were not affected by whether he
used metropolitan areas, counties or groups of counties. TR 1757-58.

1 example, that consumers under small-group coverage were limited in their ability to switch to
2 individual or large-group plans. TR 577. Yet he grouped together all of these types of
3 coverage anyway.

4 There are situations in which groups of non-interchangeable products may be
5 aggregated to form a single relevant market. For example, in *U.S. v. Philadelphia Nat'l Bank*,
6 374 U.S. 321, 83 S. Ct. 1715, 10 L. Ed. 2d 915 (1963), the Supreme Court grouped various
7 banking services, including checking accounts, credit functions, and trust administration under
8 the category of commercial banking services. But the relevant market definition must be
9 based on commercial realities faced by consumers. *Eastman Kodak Co. v. Imaging Technical*
10 *Services, supra*, 504 U.S. at 480. As the Court said in *U.S. v. Grinnell Corp.*, 384 U.S. 563,
11 572, 86 S. Ct. 1698, 16 L. Ed. 2d 778 (1966): "We see no barrier to combining in a single
12 market a number of different products or services where that combination reflects commercial
13 realities."
14

15
16 In its *Kodak* decision, the Ninth Circuit elaborated on this issue, quoting from its
17 opinion in *JBL Enterprises, Inc. v. Jhirmack Enterprises*, 698 F.2d 1011 (1983):
18

19 We commented that a "cluster approach is appropriate where the product
20 package is significantly different from, and appeals to buyers on a different
21 basis from, the individual products considered separately."

22 125 F.3d at 1204-05.

23 Dr. McCarthy's theories run counter to these authorities. Grouping the different types
24 of coverage is entirely inconsistent with the realities facing consumers, whether viewed from
25 the perspective of individuals or employers. Virtually no one switches between commercial
26 and governmental coverage, or between individual and small and large group plans. The

1 same obvious flaws infect his defined geographic market, which encompasses the entire state.
2 Virtually no one goes from Spokane to Seattle – or to Clark County – to obtain basic health
3 care, yet Premera’s economist includes the whole state in a single market. While this
4 approach does mask Premera’s dominance in Eastern Washington, it is hardly consistent with
5 the realities facing consumers. Thus it is not surprising that Dr. Gold concluded that Dr.
6 Leffler’s market-share analysis is more reasonable than that of Premera’s economist, (TR
7 1956-57) and that Dr. Gold used Dr. Leffler’s market shares in his study. TR 1958.

9 Dr. McCarthy’s analysis was based in substantial part in purported instances of
10 product line expansion by insurers, and geographic expansion into Eastern Washington. On
11 the basis of this evidence, he asserted that entry into Eastern Washington is easy. TR 524-26.
12 Dr. Leffler reviewed the evidence relied on by Dr. McCarthy. He concluded that this
13 evidence did not include a single instance of successful expansion into Eastern Washington or
14 successful expansion into commercial insurance by an insurer previously specializing in
15 governmental coverage. TR 1766-69.¹³

17 Dr. Leffler testified that he defined the relevant markets using the analytical
18 framework of the *Merger Guidelines*. TR 1753-56. Under the *Merger Guidelines*, the
19 relevant market is defined solely on the basis of alternatives available to consumers:

21 Market definition focuses solely on demand substitution factors – i.e., possible
22 consumer responses. Supply substitution factors – i.e., possible production
23 responses – are considered elsewhere in the Guidelines in the identification of
24 firms that participate in the relevant market and the analysis of entry.

23 Exhibit P-96 at 7.

25 ¹³ In his pre-filed responsive testimony, Dr. Leffler provided an even more thorough review of Dr.
26 McCarthy’s purported instance of entry and expansion. Exhibit S-54 at 7-11. Dr. Leffler demonstrated that of the
19 purported instances of entry and expansion cited by Dr. McCarthy, only the entry of Regence Asuris has any

1 Premera's economist based his statewide, all-products market on two flawed
2 assumptions. First, as discussed above, he wrongly interpreted purported instances of
3 expansion and entry and concluded that entry into Eastern Washington is easy. Dr. Leffler's
4 testimony included the point-by-point refutation of these incorrect interpretations cited above.
5 Second, Dr. McCarthy claimed that the DOJ and FTC do not actually apply the *Merger*
6 *Guidelines* as they are written. Instead, he claimed that the agencies consider supply
7 responses in defining relevant markets. This claim is not only clearly inconsistent with the
8 unambiguous text of the *Guidelines*. It is also inconsistent with the one case referred to by Dr.
9 McCarthy in this connection, *U.S. v. Aetna Inc. and The Prudential Insurance Co.* (hereafter
10 "*Aetna*"). As Dr. McCarthy conceded in his testimony, (TR 581-86), in *Aetna*:

- 12 1. The DOJ did not define the product market to include commercial and
13 governmental products. The market included only commercial products.
- 14 2. The DOJ did not even include both HMO and PPO products. The defined
15 market was limited to HMO products.
- 16 3. The geographic market was limited to the counties included in the Dallas-Ft.
17 Worth and Houston MSA, not the whole state.

18 Further, in considering the weight to give Dr. McCarthy's unsubstantiated claim that
19 the DOJ and FTC apply the *Guidelines* contrary to the way that the agencies wrote them, the
20 Commissioner should take into account the relative experience of Dr. Leffler and Dr.
21 McCarthy in this area. In the past four years alone, Dr. Leffler has testified in deposition or
22 trial in the 28 cases. *See generally* Exhibit S-16. In addition, he has consulted with the DOJ
23 or FTC in 16 different cases, beginning with the FTC investigation of the Chevron-Gulf Oil
24 merger, and continuing through his work on *U.S. v. Microsoft*. Most of these cases and

25
26 significance. And the market penetration by unbranded Asuris is a fraction of the penetration by Regence in the
counties in which it sells as Blue Shield.

1 investigations required his analysis of the relevant market, (TR 1749-50), and in all of his
2 work for the federal enforcers and in other cases he has used the approach described in the
3 *Merger Guidelines* for defining relevant markets. TR 1756. Dr. McCarthy has never been
4 retained to work on a case by the FTC or DOJ. TR 592-93.

5
6 Even if there were some doubt about the soundness of Dr. Leffler's approach, which
7 there is not, the Commissioner should consider which economist is generally more credible.
8 Dr. Leffler offered a balanced analysis based on a careful investigation that included field
9 interviews of more than 50 executives and managers of firms participating in the Washington
10 health care market. Exhibit S-17 at 9. These firms included seven brokerage firms, nine
11 competing health carriers, twelve hospitals and physicians clinics, four large buyers, and
12 Premera. Dr. Leffler's conclusions reflect his impartial approach to his investigation: some
13 favor Premera and some disfavor Premera. For example, he found that Premera has no market
14 power in Western Washington; that it has market power as a seller in Eastern Washington but
15 that power is constrained by OIC regulations and Premera's pricing policies, and that Premera
16 has exercised market power as a buyer in Eastern Washington.

17
18 Dr. McCarthy's 'field investigation' consisted of three telephone interviews with
19 brokers, each lasting 30 to 45 minutes. Neither he nor anyone else at NERA spoke with a
20 single physician, hospital, buyer, or insurer other than Premera except for one broker that
21 offers limited coverage. TR 605-07. With regard to the impartiality and balance of Dr.
22 McCarthy's work, the Commissioner will be hard pressed to find a single thing that Dr.
23 McCarthy has said that disfavors Premera, except for some of his concessions during his cross
24 examination.
25
26

1 **5. The evidence of Premera's market power on the buying side is even more**
2 **compelling.**

3 Looking at whether Premera has market power as a buyer of provider services, Dr.
4 Leffler found that Premera not only dominates the market in Eastern Washington, but that it
5 has exploited its dominance. Premera's market share there is 73 percent, or 70 percent if
6 estimated self-insurance is taken into account. TR 1771-72. There is no OIC regulation to
7 constrain Premera's use of its dominance on the buying side. Dr. Leffler demonstrated that
8 Premera has exploited its dominance in two ways. First, he compared Premera's provider fees
9 in the Spokane area to those of Regence Asuris and First Choice. TR 1772-73, 1775-76,
10 Exhibit S-115.

11
12 Second, he compared Premera's reimbursements in Eastern Washington, where it is
13 dominant, to its reimbursements in Western Washington, where it is not dominant.¹⁴ These
14 comparisons showed Premera's actual exercise of its market power in Eastern Washington.
15 TR 1776-77.

16 In *U.S. v. Microsoft Corp.*, the Court of Appeals for the D.C. Circuit affirmed a
17 finding of an entry barrier based on interrelated brand preferences for Windows of both
18 consumers and software developers:
19

20 That barrier--the "applications barrier to entry"--stems from two
21 characteristics of the software market: (1) most consumers prefer
22 operating systems for which a large number of applications have
 already been written; and (2) most developers prefer to write for
 operating systems that already have a substantial consumer base.

23 ¹⁴ During cross examination of Dr. Leffler, counsel for Premera referred to testimony by Audrey
24 Halvorson that Dr. Leffler's analysis of Premera's reimbursements based on its area factors did not take into
25 account that the area factors reflect more than provider reimbursements. Ms. Halvorson said the same thing in
26 her pre-filed direct testimony, and Dr. Leffler showed in his pre-filed responsive testimony that her criticism was
 ill-founded. Exhibit S-54 at 14-17. Dr. Leffler examined whether the other elements of Premera's area factors
 would affect his results significantly and determined that they did not. *Id.* Further, to eliminate any possible
 doubt he specifically asked Premera whether his analysis was correct, and Premera told him that it was correct.
 Id.; TR 1776-77.

1 This "chicken-and-egg" situation ensures that applications will
2 continue to be written for the already dominant Windows, which
3 in turn ensures that consumers will continue to prefer it over
4 other operating systems.

5 253 F.3d 34, 54 (2001)(citation to record omitted).

6 The same chicken-and-egg analogy applies here. Premera has used its dominant share
7 of the commercially-insured patients to get bigger discounts from providers and a large
8 network. And the lower provider reimbursements and larger network allow it to sell to more
9 consumers.

10 All that protects consumers in Eastern Washington from increased Premera premiums
11 are the constraints of OIC regulation and Premera's current pricing policies. But a conversion
12 to a public company would bring new pressures to Premera to improve its operating margins.
13 For-profit companies must shift their focus from the best interests of the subscribers to their
14 own bottom line and shareholder/investors. TR 1102-03, 1115, 1363, 2213-16, 2014, 2152.
15 According to the OIC Staff's investment banker and legal consultants, investors will want to
16 see profits increase and stock values rise. TR 1430, Exhibit S-33 at 58. Public companies are
17 measured by the increase in profit margins. TR 1699-1701, 1738. To increase margins,
18 Premera must either raise rates or lower reimbursement rates. Exhibit S-20 at 120, 122. Dr.
19 Leffler testified that although Premera has market power over provider reimbursements in
20 most parts of Eastern Washington, generally that power appears to have been largely
21 exploited. Exhibit S-17 at 4. Thus, Premera has limited ability to improve margins by further
22 reducing provider reimbursements.

23 Premera has limited ability to reduce administrative costs. TR 1678-1977; Exhibit S-20
24 at 121. Thus, Premera will have to rely heavily on increases in premiums to attain higher
25
26

1 margins. Premera will need to increase rates for the small group (2% to 4%) and individual
2 (8% to 10%) markets in Eastern Washington to meet target margins after conversion. TR
3 1679, 1955-56, Exhibit S-20 at ES-6. Rates could increase in the individual and small group
4 contract lines in Eastern Washington by at least a few percentage points to meet investor
5 expectations. TR 1955-56, 2000. Dr. Keith Leffler also stated that in parts of Eastern
6 Washington, Premera has the market dominance and the market power to raise premiums
7 above competitive levels. TR 1755, 1764, 1769; Exhibit S-17 at 23, 31-33.

9 Although Premera is restrained to some extent from increasing premiums in excess of
10 healthcare trend in Eastern Washington due to regulatory considerations, this is not the case
11 where a new plan is introduced in Eastern Washington since it would not be subject to the
12 revenue neutral requirement mandated by Washington law. TR 1031, 1872-75, 2024-26.
13 Thus, Premera would not be required to adjust rates in Western Washington to compensate for
14 rate increases in Eastern Washington.
15

16 This means that Premera could raise its rates in excess of the health care trend in
17 Eastern Washington notwithstanding its protestations to the contrary. Premera's board of
18 directors may be compelled to take such action as the result of the fiduciary duty owed to
19 shareholders. Although one cannot predict with certainty Premera's action in this regard, the
20 evidence is persuasive that Premera is likely to increase its rates to satisfy shareholder
21 expectations. The nature of the determination that the Commissioner is required to make
22 under RCW 48.31B.015(4)(a)(iv) and (vi) and 48.31C.030(5)(a)(ii)(C)(II) and (IV) is to
23 predict what the impact of the conversion on subscribers and the insurance-buying public.
24 This was recognized by the Kansas Supreme Court in a similar proceeding in which similar
25
26

1 statutory standards were applied. *Blue Cross & Blue Shield of Kansas, Inc. v. Praeger*, 276
2 Kan. 232, 75 P.3d 226, 252-253 (2003).

3 Premera submitted Economic Assurances (Exhibit E-8 to Commissioner's Exhibit 2,
4 Revised Form A Statement) that are proposed to remain in effect for two years from the date
5 of conversion. The assurances are Premera's response to PwC's finding that Premera could
6 raise individual and small group contract premium rates in Eastern Washington to meet target
7 margins. Premera seeks to assuage the Commissioner by promising not to vary its current rate
8 methodology with respect to its individual and small group contracts which, if followed, will
9 not result in rates being increased in Eastern Washington for those lines of business in excess
10 of the healthcare trend. If the Commissioner determines to approve the Form A, the proposed
11 two-year period is woefully inadequate taking into consideration the time needed for the OIC
12 to properly review Premera's compliance with the assurances. TR 1866-75; Exhibit S-69, S-
13 116. Thus, to protect consumers in Eastern Washington from large premium increases, it is
14 important that Premera be required to adhere to a three-year term as a condition if the Form A
15 is approved.
16
17

18 **D. The Commissioner should disapprove Premera's application because its**
19 **implementation will result in entrenchment of the current board of directors and**
20 **executive management and thus be harmful to the insurance buying public.**

21 Premera's application serves to entrench its current board of directors and executive
22 management thus, creating harm to the insurance buying public. Premera's executives and the
23 board members are positioned to benefit significantly from this conversion. TR 769-70, 771.
24 The greatest portion of the value of the additional compensation will be derived from the
25 issuance of stock options. TR 1382-1383, 1690. Again, despite the incredible testimony of
26

1 persons such as Brian Ancell (TR 843-44), these board members and senior management are
2 likely to be recipients of major financial gains when these options are exercised.

3 Further, the Blue Cross Blue Shield Association's (BCBSA) rules have the same effect
4 of preserving and protecting current management. The BCBSA's license agreement with
5 Premera states that, "the Plan's (Premera's) license to use the Licensed Marks and Name shall
6 automatically terminate effective: (d) ten business days after individuals who at the time the
7 Plan went public constituted the Board of Directors of the Plan . . . cease for any reason to
8 constitute a majority of the Board of Directors." Exhibit C-2, Exhibit G-20, section 9(d)(iii)
9 at 5a. This requirement firmly entrenches the current board unless Premera wants to risk the
10 loss of the Blues mark.
11

12 New Premera's proposed articles of incorporation are designed to ensure that change
13 of the makeup of the board will be kept to a minimum if it occurs at all by dictating when,
14 how, and in what circumstances shareholders or other "outsiders" are allowed to nominate
15 someone for the Premera board. For example, Section 5(b)(2) of Article III of New Premera's
16 proposed articles of incorporation states that, "the individual must be nominated by a
17 shareholder or shareholder group who (i) shall have been the beneficial owner of **more than 5**
18 **percent of the corporation's capital stock** for a continuous period of at least two years."
19 Exhibit C-2, Exhibit B-1 at 9. But, the BCBSA restricts individual ownership (not including
20 any member of the BCBSA) to less than 5%, so this provision, by design, can never be
21 fulfilled by an individual shareholder. Only a shareholder group or institutional investor can
22 meet the "more than 5%" requirement.
23
24
25
26

1 However, Section 5(d) of the same article states that "If there is more than one
2 nominating shareholder eligible to nominate a director . . . only the nominating shareholder
3 with the largest beneficial ownership shall be permitted to nominate a director." Exhibit C-2,
4 Exhibit B-1 at 12. This provision allows only one shareholder at a time (the biggest) to
5 nominate potential directors. Furthermore, a shareholder may only nominate a director when
6 a vacancy occurs or when a current director reaches the end of their term. In all other
7 circumstances, any newly created directorships or any vacancies resulting from the removal,
8 resignation, death or a director is filled by an affirmative vote of an independent board
9 majority. Exhibit C-2, Exhibit B-1, section 7, pp. 12-13; TR 1316-17.
10

11 Premera has also built into its proposed articles of incorporation, both for New
12 Premera and the foundations, mechanisms that give existing board members control over
13 "people that fit in" with the current demographic by allowing the current board to veto all of
14 the foundations proposed nominees. This attitude became evident when Kent Marquardt
15 testified that "there really needs to be the right chemistry of what the board looks like" in the
16 context of reserving the right to veto all foundation nominees to the board. TR 1133-34.
17

18 Premera has asserted that to ensure quality service to subscribers, it must remain a
19 local, independent company. TR 152-153. But quality of service has nothing to do with
20 whether the company is local or independent. TR 153-56. In fact, there are examples of
21 acquisitions of local, independent companies where services or performance were improved
22 after acquisition. TR 501. Further, acquisition is a disadvantage to management because
23 management loses control. TR 499
24
25
26

1 Premera has also claimed that conversion is necessary to raise its risk-based capital
2 percentage ("RBC"). Yet its most recent RBC level, 433%, is adequate to continue in
3 business. TR 184. It clearly exceeds the level necessary to operate within the State of
4 Washington. RCW 48.43.300-.325. Further, Premera's RBC level has improved significantly
5 since 2002 as a non-profit and attainment of the 500% RBC level will require capital in an
6 amount less than \$72 million. TR 498, 1360. Premera shows no signs of a company that is
7 suffering from capital constraints. TR 1360-61.

9 That leaves a real concern that the reason for the conversion is to enrich the board and
10 management. TR 2040-41. Such a reason only serves to be a hazard to the insurance buying
11 public.

12 **E. In the event the Form A is approved, 85% of the shares of New Premera should be**
13 **allocated to the Washington Foundation and 15% to the Alaska Foundation.**

14 As part of the Commissioner's review in this matter, a determination will need to be
15 made of the allocation split between the States of Washington and Alaska. As part of their
16 engagements, The Blackstone Group ("Blackstone") and PricewaterhouseCoopers (hereafter
17 "PwC") reviewed the relevant data to assist the Commissioner in determining a fair allocation
18 of the shares of New Premera between the proposed Washington and Alaska foundations.
19 Statutory RCW 24.03.225 for this. Blackstone conducted an investment banking analysis of
20 relative ownership that resulted in a range for Washington's relative contribution to Premera
21 of 83% to 89%. See Exhibit S-5; S-6. PwC engaged in an actuarial analysis that resulted in a
22 range for the Washington foundation's share of the stock of New Premera of 82% to 88%
23 with the midpoint of the range at 85%. See Exhibit S-23 at 4, S-24 at ES-4. During his
24
25
26

1 testimony, Deputy Commissioner Odiorne recommended adoption at the PwC range
2 midpoint: 85%. TR 2369.

3 By letter dated May 10, 2004, the Alaska Division of Insurance (hereafter "ADI")
4 Staff accepted the Commissioner's invitation and submitted a statement relating to the
5 allocation issue, which was then offered and admitted into evidence. See S-123. The
6 Commissioner granted the OIC Staff's request to respond to the ADI statement. This
7 response was filed on May 25, 2004 and included a review from Blackstone and
8 Memorandum from PwC.

9
10 **F. In the event the Commissioner is inclined to approve Premera's application,**
11 **certain additional conditions should be made.**

12 The Commissioner has authority to impose additional conditions on Premera even if
13 he is inclined to approve the application. RCW 48.31C.030(5)(a)(ii)(C). At the hearing,
14 Deputy Commissioner Odiorne described what those additional conditions should be and the
15 reasons for them. TR 2366-82, 2402-53. Those conditions are as follows:

16 *1. Condition the closing on approval of the Alaska and Oregon Insurance*
17 *Commissioners and any required action by the Washington Attorney General, with*
18 *85% of Premera's assets transferring to the Washington Foundation and 35 % to the*
Alaska Foundation.

19 *2. Eliminate the requirement for the foundations to sell down to 80 % of the*
20 *outstanding stock by the end of the first year.* Blackstone Group testified that the six
21 month lockout period and any adverse markets could significantly impact the
22 Foundation's ability to sell any stock within the first year. A forced sale to get to an
23 arbitrary percentage is unreasonable, likely to be hazardous and prejudicial to the
24 insurance-buying public.

25 *3. Allow each foundation 5% minus one of stock outside of the voting trust.* Each
26 foundation is a separate legal entity, with unique goals, serving a distinct group and
these foundations should not be forced to share this 5% vote when each is clearly a
separate shareholder.

4. Remove the 10% forced sale of the Foundation's stock at the IPO as currently
required in the Unallocated Shares Escrow Agreement. There is absolutely no
requirement for this restriction either by rule or statute.

- 1 5. *Uncouple the foundation's divestiture schedules to make them separate and stand-*
2 *alone schedules.* This will allow each foundation control to sell their stock at a time
3 when they determine is the most advantageous and work to further transfer of fair
4 market value.
- 5 6. *Eliminate Premera's ability to veto all of the Foundations' director nominees.*
6 Their argument that this restriction is necessary to ensure the correct "board
7 chemistry" is plainly offensive and wholly unnecessary. The criteria laid out for a
8 board nominee is restrictive enough to ensure that at least one of the three nominees
9 will be suitable.
- 10 7. *Retain the Foundations' board representation until its ownership falls below 5%*
11 *without adding a time limit.*
- 12 8. *Eliminate the Voting Trust and Divestiture Agreement if Premera loses its mark.*
13 Premera admitted at the hearing that this would be appropriate if in fact the mark was
14 lost.
- 15 9. *Eliminate the automatic extension of the closing date beyond one year.* Premera
16 should be required to seek Commissioner approval for any extensions. Without such a
17 requirement, the fair market value of the foundations' stock may be jeopardized.
- 18 10. *Require the approval of solicitation applications.* Both parties agree that this would
19 be required prior to an IPO.
- 20 11. *Require receipt and approval of application for solicitation permit for issuing*
21 *shares under the proposed executive compensation plan.* TR 2380.
- 22 12. *Require adequate tax comfort.* Premera should be required to submit a final
23 opinion from Ernest and Young that the conversion shall be treated as a series of tax-
24 free transactions for federal income tax purposes. Additionally, Premera should be
25 required to file a final opinion from Ernest & Young that the conversion transaction
26 should not cause Premera to undergo a material ownership change under Section 382.
27 Finally, Premera would not pass on to policyholders any adverse tax consequences
28 arising from the loss of tax benefits under Section 833(b). TR 2380.
- 29 13. *Condition the conversion closing on the Fairness, IPO Procedures and Bring-down*
30 *opinions by Blackstone.* TR 2379.
- 31 14. *Require that the foundations have the right to a free vote on any transfer or*
32 *issuance of stock involving 20% or more of equity of Premera.* TR 2381-82.
- 33 15. *Insure that Washington is afforded the same guarantees as Alaska.* Premera agreed
34 to this condition at the time of hearing.
- 35 16. *Require Premera to abide by all the terms of the assurances that the Commissioner*
36 *accepts and failure to comply with these assurances would be deemed a violation of the*
37 *Holding Company Acts and subject Premera to the penalties of those Acts.* TR 2380.
- 38 17. *That the IPO will close within twelve months of the final approval by the Attorney*
39 *General of Washington, the Alaska Commissioner, the Oregon Commissioner subject*
40 *only to extensions granted by the Commissioner on application and good cause.*

1 18. *Redefine the disqualification from eligibility for an independent board member if*
2 *the candidate, or his or her employer, accounts for 2% or \$1 million of Premera's*
3 *revenue, whichever is lesser.* TR 1473-1475, 1289-92.


4 IV. CONCLUSION

5 Based on the foregoing as well as the documents, exhibits, and testimony presented at
6 the hearing on this matter, the OIC Staff respectfully request that the Commissioner
7 disapprove the application in its current form. In the event the Commissioner is inclined to
8 approve the application, the OIC Staff request that the additional conditions as proposed by
9 Deputy Commissioner Odiorne at the hearing be imposed on the transaction.

10 DATED this 28th day of May, 2004.

11 CHRISTINE O. GREGOIRE
12 Attorney General

13
14 MELANIE C. DELEON
15 Assistant Attorney General
16 WSBA No. 30100

17 
18 JOHN E. HAMJE
19 Special Assistant Attorney General
20 WSBA No. 32400
21 Attorneys for Office of the Insurance
22 Commissioner's Staff
23
24
25
26

1
2
3
4
5
6
7 **BEFORE THE WASHINGTON**
8 **OFFICE OF INSURANCE COMMISSIONER**

9 In the Matter of

No. G02-45

10 THE APPLICATION REGARDING THE
11 CONVERSION AND ACQUISITION OF
12 CONTROL OF PREMIER BLUE CROSS
AND ITS AFFILIATES

CERTIFICATE OF SERVICE

13 I, Patti Hamblin, certify that on May 28th, 2004, I served a copy of the following
14 documents:

- 15 1. OIC STAFF'S POST HEARING BRIEF
16 2. CERTIFICATE OF SERVICE
17

18 On all parties below as follows:


Service To:	Service Perfected By:
19 Carol Sureau	<input type="checkbox"/> By United States Mail
20 Deputy Insurance Commissioner	<input type="checkbox"/> By Overnight Delivery
Office of the Insurance Commissioner	<input type="checkbox"/> By Legal Messenger Service
5000 Capitol Blvd.	<input checked="" type="checkbox"/> By hand Delivery
21 Tumwater, WA 98501	<input type="checkbox"/> Campus Delivery
P.O. Box 40255	<input checked="" type="checkbox"/> By Facsimile
22 Fax: (360) 586-3109	<input checked="" type="checkbox"/> By E-Mail
23 John Hamje OIC	<input type="checkbox"/> By United States Mail
24 Office of the Insurance Commissioner	<input type="checkbox"/> By Overnight Delivery
P.O. Box 40259	<input type="checkbox"/> By Legal Messenger Service
25 Olympia, WA 98504-0259	<input checked="" type="checkbox"/> By hand Delivery
26	<input type="checkbox"/> By Facsimile
	<input checked="" type="checkbox"/> By E-Mail

1	Service To:	Service Perfected By:
2	James Odiorne	<input type="checkbox"/> By United States Mail
3	Deputy Commissioner	<input type="checkbox"/> By Overnight Delivery
4	Office of the Insurance Commissioner	<input type="checkbox"/> By Legal Messenger Service
5	P0 Box 40259	<input checked="" type="checkbox"/> By hand Delivery
6	Olympia, WA 98504-0259	<input type="checkbox"/> Campus Delivery
7	Fax: (360) 586-2022	<input checked="" type="checkbox"/> By Facsimile
8		<input checked="" type="checkbox"/> By E-Mail
9	John P. Domeika	<input checked="" type="checkbox"/> By United States Mail
10	Senior Vice President	<input type="checkbox"/> By Overnight Delivery
11	General Counsel	<input type="checkbox"/> By Legal Messenger Service
12	Premera Blue Cross	<input type="checkbox"/> By hand Delivery
13	P0 Box 327, MS 316	<input checked="" type="checkbox"/> By Facsimile
14	Seattle, WA 98111-0327	<input checked="" type="checkbox"/> By E-Mail
15	7001 220 th St. S.W.	
16	Building 3, MS 316	
17	Mountlake Terrace, WA 98043-2124	
18	Fax: (425) 670-5787	
19	Thomas Kelly	<input type="checkbox"/> By Overnight Delivery
20	Preston Gates & Ellis LLP	<input checked="" type="checkbox"/> By United States Mail
21	925 Fourth Ave Ste 2900	<input type="checkbox"/> By Legal Messenger Service
22	Seattle, WA 98104-1158	<input type="checkbox"/> By hand Delivery
23	Fax: (206) 623-7022	<input checked="" type="checkbox"/> By Facsimile
24		<input checked="" type="checkbox"/> By E-Mail
25	Eleanor Hamburger	<input checked="" type="checkbox"/> By United States Mail
26	Columbia Legal Services	<input type="checkbox"/> By Overnight Delivery
27	101 Yesler Way, Suite 300	<input type="checkbox"/> By Legal Messenger Service
28	Seattle, WA 98104	<input type="checkbox"/> By hand Delivery
29	Fax: (206) 382-3386	<input checked="" type="checkbox"/> By Facsimile
30		<input checked="" type="checkbox"/> By E-Mail
31	Jeff Coopersmith	<input checked="" type="checkbox"/> By United States Mail
32	Coopersmith Health Law Group	<input type="checkbox"/> By Overnight Delivery
33	1325 Fourth Ave Ste 1740	<input type="checkbox"/> By Legal Messenger Service
34	Seattle, WA 98101	<input type="checkbox"/> By hand Delivery
35	Fax: (206) 262-8001	<input checked="" type="checkbox"/> By Facsimile
36		<input checked="" type="checkbox"/> By E-Mail
37	Michael Madden	<input checked="" type="checkbox"/> By United States Mail
38	Michael S. Shachat	<input type="checkbox"/> By Overnight Delivery
39	Bennett Bigelow & Leedom, P.S.	<input type="checkbox"/> By Legal Messenger Service
40	1700 Seventh Avenue, Suite 1900	<input type="checkbox"/> By hand Delivery
41	Seattle, WA 98101	<input checked="" type="checkbox"/> By Facsimile
42	Fax: (206) 622-8986	<input checked="" type="checkbox"/> By E-Mail
43	Amy McCullough	<input checked="" type="checkbox"/> By United States Mail
44	James Davis	<input type="checkbox"/> By Overnight Delivery
45	Alaska Legal Services Corporation	<input type="checkbox"/> By Legal Messenger Service
46	1016 W 6 th Ave Ste 200	<input type="checkbox"/> By hand Delivery
47	Anchorage, AK 99501	<input checked="" type="checkbox"/> By Facsimile
48	Fax: (907) 279-7417	<input checked="" type="checkbox"/> By E-Mail
49		
50		

Service To:	Service Perfected By:
Ardith Lynch	<input checked="" type="checkbox"/> By United States Mail
University of Alaska	<input type="checkbox"/> By Overnight Delivery
PO Box 755160	<input type="checkbox"/> By Legal Messenger Service
Fairbanks, AK 99775-5160	<input type="checkbox"/> By hand Delivery
Butrovich Bldg, Ste 203	<input checked="" type="checkbox"/> By Facsimile
910 Yukon Dr.	<input checked="" type="checkbox"/> By E-Mail
Fairbanks, AK 99775	
907-474-7259	
Fax: (907) 474-5574	
Judge George Finkle	<input type="checkbox"/> By United States Mail
1411 Fourth Avenue S. Suite 200	<input type="checkbox"/> By Overnight Delivery
Seattle WA 98101	<input type="checkbox"/> By Legal Messenger Service
206-223-1669	<input type="checkbox"/> By hand Delivery
Fax 206-223-0450	<input type="checkbox"/> By Facsimile
	<input type="checkbox"/> By E-Mail

I certify under penalty of perjury under the laws of the State of Washington that the foregoing is true and correct.

DATED this 28th day of May, 2004 at Olympia, Washington.


Patti Hamblin, Legal Assistant